NOVARTIS
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
The Effects of Tegaserod vs. Placebo on Whole Gut Transit Time in Patients With Chronic Constipation and Dyspepsia
- Conditions
- Constipation and Dyspepsia
- First Posted Date
- 2006-01-16
- Last Posted Date
- 2016-03-04
- Lead Sponsor
- Novartis
- Registration Number
- NCT00277550
Efficacy, Safety, and Tolerability of Oxcarbazepine Monotherapy in Children With Partial Seizures
- Conditions
- Epilepsy, Partial Seizures
- First Posted Date
- 2006-01-12
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 60
- Registration Number
- NCT00275912
- Locations
- 🇷🇺
Russian State Medical University clinically based on Russian Pediatric Clinical Hospital, Moscow, Russian Federation
🇷🇺Regional Pediatric Clinical Hospital №1 EkaterinburgRegional Pediatric Clinical Hospital №1, Ekaterinburg, Russian Federation
🇷🇺Moscow Scientific Research Institute of Pediatrics and Pediatric Surgery, Moscow, Russian Federation
Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)
- Conditions
- Age Related Macular Degeneration
- Interventions
- First Posted Date
- 2006-01-12
- Last Posted Date
- 2011-03-16
- Lead Sponsor
- Novartis
- Target Recruit Count
- 353
- Registration Number
- NCT00275821
- Locations
- 🇨🇭
Novartis, Basel, Switzerland
Safety and Efficacy of Oxcarbazepine Monotherapy in Adults With Partial Seizures
- Conditions
- Epilepsy, Partial Seizures
- First Posted Date
- 2006-01-12
- Last Posted Date
- 2007-11-30
- Lead Sponsor
- Novartis
- Target Recruit Count
- 80
- Registration Number
- NCT00275925
- Locations
- 🇷🇺
Neurology and Neurosurgery Department of the Russian State Medical University, Moscow, Russian Federation
🇷🇺Neurology and Neurosurgery Department of the Moscow State Medico-stomatology University, Moscow, Russian Federation
🇷🇺Neurology Department of the Moscow region Research Institute named after M.F. Vladimirskiy, Moscow, Russian Federation
Valsartan/Hydrochlorothiazide Combination in the Treatment of Severe Hypertension
- Conditions
- Hypertension
- First Posted Date
- 2006-01-09
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 607
- Registration Number
- NCT00273299
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Efficacy and Safety of Lumiracoxib
- Conditions
- Osteoarthritis
- First Posted Date
- 2005-12-20
- Last Posted Date
- 2012-05-21
- Lead Sponsor
- Novartis
- Target Recruit Count
- 330
- Registration Number
- NCT00267215
- Locations
- 🇩🇪
Novartis, Nuernberg, Germany
Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic Asthma
- Conditions
- Allergic Asthma
- Interventions
- First Posted Date
- 2005-12-20
- Last Posted Date
- 2016-09-14
- Lead Sponsor
- Novartis
- Target Recruit Count
- 275
- Registration Number
- NCT00267202
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
Omalizumab in Adult and Adolescent Patients With Severe Persistent Allergic Asthma
- First Posted Date
- 2005-12-13
- Last Posted Date
- 2018-06-29
- Lead Sponsor
- Novartis
- Target Recruit Count
- 406
- Registration Number
- NCT00264849
Efficacy and Safety of Aliskiren and Atenolol in Adults (>18) With Mild to Moderate Hypertension
- Conditions
- Hypertension
- First Posted Date
- 2005-12-06
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 693
- Registration Number
- NCT00262236
- Locations
- 🇨🇭
Novartis, Basel, Switzerland
A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren in Patients With High Blood Pressure
- Conditions
- Hypertension
- First Posted Date
- 2005-12-02
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 641
- Registration Number
- NCT00260923
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States